Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin) (ECLIPSE 03)

This study has been completed.
Sponsor:
Information provided by:
Biosite
ClinicalTrials.gov Identifier:
NCT00933738
First received: July 3, 2009
Last updated: June 21, 2011
Last verified: June 2011

July 3, 2009
June 21, 2011
December 2009
December 2010   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00933738 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Evaluation of the Accuracy of the INRatio Prothrombin Time (PT) Monitoring System With a New Test Strip for the Oral Anticoagulation Therapy Patient in the Presence of Heparin and Low Molecular Weight Heparin (e.g., Enoxaparin or Dalteparin)
Not Provided

This is a multi-center study designed to evaluate the heparin insensitivity of the INRatio Prothrombin Time (PT) Monitoring System, utilizing an INRatio test strip additionally modified for low sample volume. The INRatio test strip is used for the quantitative determination of PT and International Normalized Ratio (INR) results in fingerstick blood from subjects on oral anticoagulation therapy (OAT) with warfarin. This study is designed to evaluate the accuracy of the modified INRatio test strip during heparin-warfarin bridge therapy with unfractionated heparin (UH) or low molecular weight heparin (LMWH), such as enoxaparin or dalteparin. These INR results will be compared to the INR results obtained on plasma from the same subjects as analyzed at a central laboratory with the heparin-insensitive reference method: the Sysmex CA-560 System. The levels of UH or LMWH in the plasma samples will be assessed using activated partial thromboplastin time (aPTT) and anti-factor-Xa assays respectively.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

Plasma samples to be retained for reference testing and banking.

Non-Probability Sample

Patients undergoing heparin bridging onto OAT with warfarin.

Coagulation
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
150
March 2011
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adults (18 years of age or older).
  • Willing and able to provide written informed consent and comply with study procedures.
  • Receiving warfarin/heparin bridge therapy.
  • Therapy with both warfarin and one of the heparins listed below must have been initiated for at least 12 hours before the first study specimens are obtained.
  • UH (last known aPTT prior to enrollment (if available†) must confirm heparin has been administered)
  • Dalteparin (last known anti-factor Xa prior to enrollment (if available†) must confirm heparin has been administered)
  • Enoxaparin (last known anti-factor Xa prior to enrollment (if available†) must confirm heparin has been administered) † If a pre-study aPTT or anti-factor Xa is not available, subsequent testing of the study phlebotomy or a phlebotomy as a part of routine medical care taken before or during the time of the study phlebotomy must confirm the presence of heparin (unfractionated or low molecular weight) in order for that data point to be included in the analysis.

Exclusion Criteria

  • Known or suspected hematocrit less than 25 or greater than 55%;
  • Auto-immune disorders known to interfere with INR measurements, such as lupus or anti-phospholipid syndrome (APS)
  • Already participated in this specific study
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00933738
BSTE-0120.a
No
Keith Gran / Sr. Clinical Trial Manager, Biosite, Incorporated a subsidiary of Inverness Medical Innovations
Biosite
Not Provided
Not Provided
Biosite
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP